LXEO

Lexeo Therapeutics (LXEO)

About Lexeo Therapeutics (LXEO)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Details

Daily high

$9.88

Daily low

$9.54

Price at open

$9.68

52 Week High

$10.56

52 Week Low

$1.45

Market cap

712.4M

Dividend yield

0.00%

Volume

711,879

Avg. volume

1.0M

P/E ratio

-3.61

Lexeo Therapeutics News